Vimta Labs

Vimta Labs delivered a strong Q4 FY26 with revenue of ₹112 croreCurrent reported value: ₹112 crore. No comparable prior figure is available in the source record. (+16.6Current reported value: 16.6. No comparable prior figure is available in the source record.% YoY) and EBITDA of ₹42.1 croreCurrent reported value: ₹42.1 crore. No comparable prior figure is available in the source record. (+21.5% YoY), driven by robust performance in pharma and food testing. EBITDA margin expanded to 37.6%Current reported value: 37.6%. No comparable prior figure is available in the source record. (+150 bps YoY), among the best in the industry. The company entered biologics CRD services, with infrastructure ready and client discussions underway. Management targets maintaining 20-25% revenue CAGR and sustaining margins around 35%, though near-term headwinds from geopolitical tensions and input cost inflation pose risks. The balance sheet remains net debt-free with ₹65 crore cash. Key risk: any escalation in global trade disruptions could impact client spending and delay growth.